Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Galnon

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Galanin's influence on monoaminergic neurotransmission, together with its discrete CNS distribution in corticolimbic brain areas… Expand
Review
2005
Review
2005
Galnon is a low-molecular weight galanin receptor ligand, with affinity towards the three galanin receptors in the micromolar… Expand
2005
2005
Galnon was first reported as a low molecular weight non-peptide agonist at galanin receptors [Saar et al. (2002) Proc. Natl. Acad… Expand
Highly Cited
2005
Highly Cited
2005
Selective serotonin reuptake inhibitors, such as fluoxetine (FLX), are the most commonly used drugs in the treatment of major… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2005
2005
The impairment of cognitive performance by galanin administration in rodents indicates a possible modulating effect of this… Expand
2004
2004
Galanin is a neuropeptide that has been implicated in multiple bioactivities, inter alia eating disorders. In this study, we have… Expand
Highly Cited
2004
Highly Cited
2004
The pharmacological exploitation of the galanin receptors as drug targets for treatment of epilepsy, depression, and pain has… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 5
Highly Cited
2003
Highly Cited
2003
Much research has focused on pathways leading to opiate addiction. Pathways opposing addiction are more difficult to study but… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2003
2003
We have examined the effect of systemically administered galnon, a novel low-molecular weight agonist of galanin receptors, on… Expand
Highly Cited
2002
Highly Cited
2002
Galanin is a neuropeptide with a wide variety of biological functions, including that of a strong endogenous anticonvulsant. No… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3